MODERN ASPECTS OF MANAGEMENT OF PATIENTS WITH HELICOBACTER PYLORI-ASSOCIATED DISEASES: RECOMMENDATIONS OF THE EUROPEAN MAASTRICHT-V CONSENSUS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Prevention of gastric cancer is one of the main direction in the management of patients with Helicobacter pylori-associated diseases. Due to increasing resistance of H. pylori to antibiotics, quadrupletherapy with bismuth and concomitant therapy play central stage in the treatment of infection. Given the low resistance of H. pylori to clarithromycin, traditional triple therapy keeps meaning in Russia. Now it is proved that there are a lot of different microorganisms in the stomach that can influence the development of pathology. The use of probiotics helps to reduce the frequency of side effects and increases the effectiveness of H. pylori eradication.

Full Text

Restricted Access

About the authors

V. V Tsukanov

FSBEI “Federal Research Center “Krasnoyarsk Scientific Center" of the Siberian Branch of the Russian Academy of Sciences, a Separate Subdivision “Scientific Research Institute of Medical Problems of the North “

Email: gastro@impn.ru
MD, Prof., Head of the Clinical Department of the Pathology of the Digestive System in Adults and Children FRC

E. V Kasparov

FSBEI “Federal Research Center “Krasnoyarsk Scientific Center" of the Siberian Branch of the Russian Academy of Sciences, a Separate Subdivision “Scientific Research Institute of Medical Problems of the North “

A. V Vasyutin

FSBEI “Federal Research Center “Krasnoyarsk Scientific Center" of the Siberian Branch of the Russian Academy of Sciences, a Separate Subdivision “Scientific Research Institute of Medical Problems of the North “

Yu. L Tonkikh

FSBEI “Federal Research Center “Krasnoyarsk Scientific Center" of the Siberian Branch of the Russian Academy of Sciences, a Separate Subdivision “Scientific Research Institute of Medical Problems of the North “

O. V Peretyatko

FSBEI “Federal Research Center “Krasnoyarsk Scientific Center" of the Siberian Branch of the Russian Academy of Sciences, a Separate Subdivision “Scientific Research Institute of Medical Problems of the North “

References

  1. Malfertheiner P., Megraud F., O'Morain C.A., et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30.
  2. Lee Y.C., Chiang T.H., Chou C.K. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. Gastroenterology. 2016;150(5):1113-24.
  3. Ma J.L., Zhang L., Brown L.M., Li J.Y., Shen L., Pan K.F., Liu W.D., Hu Y., Han Z.X., Crystal-Mansour S., Pee D., Blot W.J., Fraumeni J.F. Jr, You W.C., Gail M.H. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treat-ments on gastric cancer incidence and mortality. J. Natl. Cancer !nst. 2012;104(6): 488-92.
  4. Wong B.C., Lam S.K., Wong W.M. Chen J.S., Zheng T.T., Feng R.E., Lai K.C., Hu W.H., Yuen S.T., Leung S.Y., Fong D.Y., Ho J., Ching C.K., Chen J.S. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004;291(2):187-94.
  5. Huang Y.K., Yu J.C., Kang W.M., Ma Z.Q., Ye X., Tian S.B., Yan C. Significance of Serum Pepsinogens as a Biomarker for Gastric Cancer and Atrophic Gastritis Screening: A Systematic Review and Meta-Analysis. PLoS One. 2015;10(11):e0142080.
  6. Thung I., Aramin H., Vavinskaya V. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment. Pharmacol. Ther. 2016;43(4):514-33.
  7. Lu H., Zhang W., Graham D.Y Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China. Eur. J. Gastroenterol. Hepatol. 2013;25(10):1134-40.
  8. Yoon S.B., Park J.M., Lee J.Y., et al. Long-term pretreatment with proton pump inhibitor and Helicobacter pylori eradication rates. World J. Gastroenterol. 2014;20(4):1061-66.
  9. Graham D.Y. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology. 2015;148(4):719-31.
  10. Bik E.M., Eckburg P.B., Gill S.R. et al. Molecular analysis of the bacterial microbiota in the human stomach. Proc. Natl. Acad. Sci. USA. 2006;103(3):732-37.
  11. Cao L., Yu J. Effect of Helicobacter pylori Infection on the Composition of Gastric Microbiota in the Development of Gastric Cancer. Gastrointest. Tumors. 2015;2(1):14-25.
  12. Цуканов В.В., Третьякова О.В., Амельчугова О.С., Каспаров Э.В., Родина Д.В., Васютин А.В., Буторин Н.Н., Тонких Ю.Л. Распространенность атрофического гастрита тела желудка у населения г. Красноярска старше 45 лет. Рос. журн. гастроэнтерол., гепатолог, колопроктол. 2012;(4):27-31.
  13. Буторин Н.Н., Бичурина Т.Б., Цуканов В.В. и др. Распространенность и клинические аспек ты пищевода Барретта у населения Восточной Сибири. Тер. арх. 2013;(1):62-5.
  14. Цуканов В.В., Селиверстова Е.В., Догадин С.А. Показатели липидного состава сыворотки крови и желчи при заболеваниях желчевыводящих путей у больных сахарным диабетом. Тер. арх. 2005;(2):15-8.
  15. Агеева Е.С., Штыгашева О.В., Цуканов В.В., Рязанцева Н.В. Иммунологические особенности течения гастродуоденальной патологии у жителей Хакасии. Иммунология. 2009;(3):162-64.
  16. Агеева Е.С., Штыгашева О.В., Рязанцева Н.В., Цуканов В.В. Молекулярно-генетические факторы, влияющие на исход инфицирования Helicobacter pylori у жителей Республики Хакасия. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2010;(4):16-21.
  17. Dicksved J., Lindberg M., Rosenquist M., et al. Molecular characterization of the stomach microbiota in patients with gastric cancer and in controls. J. Med. Microbiol. 2009;58 (Pt. 4):509-16.
  18. Eun C.S., Kim B.K., Han D.S., et al. Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods. Helicobacter. 2014;19(6):407-16.
  19. Lofgren J.L., Whary M.T., Ge Z., Muthupalani S., Taylor N.S., Mobley M., Potter A., Varro A., Eibach D., Suerbaum S., Wang T.C., Fox J.G.Lack of commensal flora in Helicobacter pylori-infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia. Gastroenterology. 2011;140(1):210-20.
  20. Lv Z., Wang B., Zhou X., Wang F., Xie Y., Zheng H., Lv N. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: A meta-analysis. Exp. Ther. Med. 2015;9(3): 707-16.
  21. Szajewska H., Horvath A., Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment. Pharmacol. Ther. 2010;32(9):1069-79.
  22. Zhang M.M., Qian W., Qin Y.Y., He J., Zhou Y.H. Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. World J. Gastroenterol. 2015;21(14):4345-57.
  23. Ивашкин В.Т., Маев И.В., Лапина Т.Л., Шептулин А.А. Рекомендации Российской Гастроэнтерологической Ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Рос. журн. гастроэнтерол., гепатол., колопроктол. 2012;(1):87-9.
  24. Цуканов В.В., Каспаров Э.В., Васютин А.В., Тонких Ю.Л. Микробиом желудка: развитие революции. Фарматека. 2016;(15):78-81.
  25. Sugano K., Tack J., Kuipers E.J. et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353-67.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies